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ABBREVIATIONS  
ACTH  Adrenocorticotropic hormone 
BMD  Bone mineral density 
BMI  Body mass index 
BP  Bodily pain 
CAH  Congenital adrenal hyperplasia 
CI  Confidence interval 
CSHI  Continuous subcutaneous hydrocortisone infusion  
CT  Computed tomography 
CYP21A2 Cytochrom  P450, Family 21, subfamily A, polypeptide 2 gene  
CYP21A2P Cytochrom  P450, Family 21, subfamily A, polypeptide 1 pseudogene 
DHEAS Dehydroepiandrosterone  
DSD  Disorders of sexual development 
DXA  Dual X-ray absorptiometry  
FSH  Follicle stimulating hormone 
GH  General health 
HC  Hydrocortisone 
HDL  High-density lipoprotein 
HRQoL Health-related quality of life  
HUNT  North-Trøndelag Health Study  
IMT  Intima-media thickness  
I2  Intron 2 
LDL  Low-density lipoprotein 
LH  Lutein stimulating hormone  
MH  Mental health 
MR  Magnetic resonance imaging 
NC   Non-classical  
17-OHP 17-hydroxyprogesterone  
PCR  Polymerase chain reaction 
PF  Physical functioning 
PRA  Plasma renin activity 
PTH  Parathyroid hormone 
21-OH  21-hydroxylase 
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21-OHD 21-hydroxylase deficiency 
QOLS  Quality of Life Scale  
RE  Role-emotional 
RP  Role-physical 
SDS  Standard deviation score 
SF  Social functioning 
SF-36  Short Form-36  
SV  Simple virilising  
SW  Salt-wasting   
TART  Testicular adrenal rest tumours 
VT  Vitality 
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SUMMARY 
 
Background 
Congenital adrenal hyperplasia (CAH) is an inherited recessive disorder, in which enzymes in 
the adrenal cortex are mutated. The most common form is caused by alterations in CYP21A2, 
the gene encoding the adrenal steroid 21-hydroxylase enzyme. The consequences are 
impaired production of cortisol and aldosterone, leading to increased ACTH driven 
production of adrenal androgens, resulting in virilisation of the female. The patients require 
life-long treatment with glucocorticoid and mineralocorticoid tablets. 
 
Objective 
No published data on CAH in Norway existed when we started our survey. Our aim was to 
obtain confident epidemiological data from Norway and to describe clinical and genetic 
aspects in adults with CAH due to 21-hydroxylase deficiency. Specific aims were to describe 
health-related quality of life and working ability, and the frequency of testicular and adrenal 
tumours.  
 
Material and methods 
Epidemiological data were obtained by scrutiny medical reports at all the University Hospitals 
in Norway and by contacting endocrinologists throughout the country. First, the patients were 
invited to a questionnaire survey including medical history, and the Short Form-36 and 
Quality of Life Scale questionnaire. Second, they were invited to participate in clinical, 
biochemical and radiological investigations at four University Hospitals, including 
anthropometric measurements, that is, dual X-ray absorptiometry scanning, adrenal computed 
tomography, testicular ultrasound, DNA sequencing of CYP21A2 and hormone analyses. 
 
Results 
We showed lower incidence of CAH than expected and especially than that of our 
neighbouring country Sweden. Fewer males than females with CAH were identified although 
equal sex ratio was expected. As a group the patients had increased working disability and 
reduced physical and mental health as compared with the normal population. The women had 
decreased fertility.                                                                                                                                                  
We found a high frequency of adrenal tumours, particularly myelolipomas, and testicular 
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adrenal rest tumours only associated with salt wasting. The patients had normal BMI but 
markedly higher fat mass, higher diastolic blood pressure and lower bone mineral density than 
the general population. We showed higher frequency of osteopenia among the men than the 
women. Near half of the women had testosterone levels above the normal range and half of 
the subjects had 17-hydroxyprogesterone (17-OHP) levels above the upper recommended 
target.We identified four novel and plausibly disease-causing CYP21A2 mutations and, as 
expected, high correspondence between genotype and clinical phenotype. The frequency of 
the underlying genetic defects was similar to published results from other Western European 
countries.   
 
Conclusion 
Adult men with CAH were missing and perhaps never diagnosed. Androgen levels and 17-
OHP-levels were poorly controlled. We found reduced BMD, impaired quality of life, and 
increased frequency of adrenal tumours, and in females impaired fertility. These findings may 
reflect inappropriate glucocorticoid and mineralocorticoid therapy and need for improvement 
of the medical treatment and general care of adults with CAH.   
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BACKGROUND 
 
Congenital adrenal hyperplasia  
 
Definition 
Congenital adrenal hyperplasia (CAH) is a spectrum of genetic disorders causing deficiencies 
in the steroidogenic enzymes in the adrenal cortex. More than 95% of CAH cases are 21-
hydroxylase deficiency (21-OHD), with defective 21-hydroxylase (21-OH) enzyme, which is 
encoded by the CYP21A2 gene (1;2). This enzyme deficiency leads to impaired conversions 
of progesterone to deoxycortisosterone, a precursor to aldosterone, and of 17-hydroxy- 
progesterone (17-OHP) to 11-deoxycortisol, which is a precursor to cortisol (Figure 1). 
Patients with 21-OHD therefore have exceedingly high levels of 17-OHP when untreated or 
undiagnosed. The condition is divided into classical CAH, which includes the salt-wasting 
(SW) and simple virilising (SV) forms, and non-classical (NC) or “late-onset” form. The SW 
entails complete lack of cortisol and aldosterone, and the SV displays a degree of cortisol 
depletion; both are accompanied by adrenocorticotropic hormone (ACTH)-driven increase in 
adrenal androgens. The NC does not have cortisol or aldosterone deficiency, but has 
manifestations of hyperandrogenism that typically presents later in childhood or in early 
adulthood. NC is a common cause of hyperandrogenism in adult woman world-wide (3). The 
second most common form of CAH is 11-ȕ-hydroxylase (CYP11 B1) deficiency with an 
incidence of one per 100 000 (4). Deficiency of 11-ȕ- hydroxylase results in decreased 
conversion of deoxycorticosterone to corticosterone, a precursor to aldosterone, and of 11-
deoxycorticosterone to cortisol and is characterised by hyporeninemic, hypokalemic 
hypertension and hyperandrogenism (4;5). These patients rarely have salt-wasting crises as 
aldosterone is synthesized by the CYP11B2 enzyme, which is unaffected in this disorder. 
Other rare disorders of adrenal steroidogenesis are aldosterone synthase deficiency 
(CYP11B2), 17-Į-hydroxylase deficiency (CYP17), 3-ȕ-hydroxysteroid dehydrogenase 
deficiency (HSD3B2) and lipoid hyperplasia (StAR; Steroid acute regulatory protein), with 
different clinical representation due to where the adrenal enzymes are blocked (Table 1) (6). 
In the following CAH refers to 21-OHD.  
12
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History 
In 1631 a famous painting of a virilised woman and her husband was made by Alfonso E.F. 
Sancick (Figure 2), which could very well be a woman with SV form of CAH.  
 
 
 
Figure 2  Painting of a virilised woman from 1631, painted by Alfonso E.F. Sancick (from 
Google). 
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The first known patient with CAH was described in 1865 by Luigi De Crecchio, a professor 
of anatomy in Napoli (7). He was doing an autopsy of a man named Giuseppe Marzo, who 
died suddenly in his forties. The professor expressed marked surprise at the findings of uterus 
and fallopian tubes in this man, who also happened to have very large adrenals. The patient 
had a six centimeter long “penis”, but no testes. At birth he was initially regarded a girl, but 
at four years of age he was reconsidered a male. As an adult he fell in love with a girl; 
however, when he proposed to marry her she ran away after realising that his birth certificate 
carried the name Guiseppina. The story goes that Guiseppe died of a broken heart, but 
probably he died of a salt-wasting crisis (8). CAH is a common cause of disorders of sexual 
development (DSD), and Giseppe’s story is still relevant in 2012.  SW CAH was a deadly 
disease until the glucocorticoids became available in the early 1950’s  as patients very often 
died of salt-wasting crisis in the neonatal period. Some milestones in the modern history of 
CAH are illustrated in Table 2.  
 
 
Table 2  Modern history of CAH. 
1920 CAH is an autosomal trait 
1937 T. Reichstein synthesized the first active substance from the adrenal cortex, 11-
deoxycortisone (11-DOC) (9) 
1949 E. C. Kendall synthesized cortisone, and the first CAH patients started treatment 
with cortisone (10) 
1949 17-hydroxyprogesterone was synthesized (11) 
1950 Nobel Prize to Reichstein, Kendall and Hench                                          
 (Hench used cortisone to treat patients with rheumatoid arthritis)  
1952 Aldosterone was isolated and synthesized (12) 
1960s The radioimmunoassays for serum hormone measurement were developed 
1977 The 21-hydroxylase gene was mapped on the short arm of chromosome 6p (13) 
1984 The 21-hydroxylase gene was cloned and the structure of the gene described (14) 
2004 Mutation was found in P450reductase, the obligate electron donor for CYP 
enzymes (15) 
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Epidemiology 
CAH due to 21-OHD deficiency is considered one of the most common inborn autosomal 
recessive disorders. The prevalence is lower than the incidence, because of deaths due to salt 
wasting crises, especially in SW born before the 1950’s. The world-wide incidence of the 
classical form of CAH, based on neonatal screening programmes with more than 6.5 million 
neonates included, has been estimated at 1/15 000 (16), but with considerable ethnical and 
geographical variation. The Yupic Eskimos in Alaska has the highest reported incidence at 
1/282 (17), in contrast to Afro-Americans in Texas, who have the lowest known incidence at 
1/42 309 (18). In Sweden, incidence at 1/9 800 was recently reported based on neonatal 
screening programs (19). In Finland, which still does not perform neonatal screening, the 
reported incidence is 1/15 000 (20) (Table 3). NC CAH is a common cause of 
hyperandrogenism in adult woman with an incidence of 1-2/1000 in the general Caucasian 
population and as high as 1-2/100 among inbred populations such as Eastern European 
(Ashkenazi) Jews (21). However, my personal experience as an endocrinologist is that we 
rarely diagnose NC in Norway.  
 
Table 3  Incidence of CAH in different contries and populations. 
Country/population   Incidence Year Neonatal 
screening 
Yupic Eskimos in Alaska (22)                 1/282 1993 + 
Réunion in the Indian Ocean (17)              1/2 141 1998 + 
Sweden (23) 1/ 9 800 1994 + 
Finland (24)         1/15 000 1995 - 
The Netherlands (25)         1/11 764 2001 +* 
Australia, states with screening (26) 1/15 488 1997 + 
Mainland France (27) 1/ 15 699 2003 + 
Great Britain (28)              1/18 000 2012 - 
Australia, states without screening (26) 1/18 034 1997 - 
Afro-Americans in USA (Texas) (18)       1/42 309 1998 + 
*Pilot screening 
17 
 
Genetics of CYP21A2 
The CYP21A2 gene encodes the 21-OH protein, which is a microsomal cytochrome P450 
enzyme essential for adrenal steroidogenesis. White et al. cloned the gene and described its 
protein structure in 1984 (14). CYP21A2 is located on the short arm of chromosome 6 (band 6 
p21.3) in the HLA class III gene region, near the genes encoding the fourth component of 
complement C4A and C4B. The CYP21A2 gene has a 98% homologous inactive pseudogene 
CYP21A1P, which is located adjacent to the active gene (Figure 3). One 21-OH gene and one 
C4 gene form one unit; these units are tandemly repeated. The CYP21A2 gene consists of ten 
exons, whereas the genes for other P450 enzymes contain seven, eight, or nine exons. The 
enzyme is at most 28% homologous to other cytochrome P450 enzymes that have been 
studied. The inactive pseudogene has an 8-base deletion in codons 110 through 112, resulting 
in a frameshift and a stop codon at codon 130; a second frameshift and a nonsense mutation 
occur farther downstream. The two CYP21 genes have nine introns and are about 3.4 kb long 
(29). The majority of the disease-causing mutations in CYP21A2 have arisen through 
interaction with CYP21A1P; the most common are deletions or large gene conversions of the 
entire CYP21A2 and/or pseudogene-derived point mutations. In a large cohort from The 
Netherlands analysis of 370 unrelated alleles revealed 31.9% deletion/conversion, 28.1%  
intron 2 (I2) splice mutation, and 12.4% with the point mutation I172N (30). Mutation 
frequencies in other Western European countries are similar (31;32).  
 
Correlations between genotype and phenotype 
The correlation between genotype and clinical phenotype in CAH deficiency is usually high 
and robust (33). In compound heterozygous cases, the mildest mutation defines the genotype 
group. Clinically the three different phenotypes are SW, SV, and NC. Based on  genotype 
four groups are recognized (34) (Table 4). The SW belongs to group Null and A, the SV to 
group B and sometimes group A or C; the NC to group C. The phenotype can change with 
age, typically with recovery from salt loss (35). Sometimes patients have residual aldosterone 
production despite severe mutations (30).  
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Figure 3  Schematic representation of the CYP21A region and the two actual genes CYP21A2 
and the pseudogene CYP21A1P. The several deleterious mutations in the 98% homologous  
pseudogene  can be transferred to CYP21A2 through recombination or gene conversion. The 
nine most common mutations are marked. RP: telometric RP gene; TNXB: centromeric TNX 
gene. From Anna Wedell (36) with permission from Karger. 
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Table 4  Genotypes in CAH grouped according to predicted severity of mutations in 
CYP21A2, their phenotype and 21-hydroxylase activity in vitro (34).                                                                 
Mutation 
group 
Common 
Mutation 
Clinical 
severity 
Phenotype Enzyme activity (in 
vitro) 
Percentage of 
normal 
Null Deletion, 
Del  8 bp E3,  
Cluster E6, L307 ins, 
Q318X and R356W 
 SW <1% 
 
A 
 
 
I2 splice 
  
SW/(SV)         
 
<2% 
B 
 
I172N  SV <10% 
C 
 
P30L 
V281L and P453S 
 SV/NC <75% 
     
 
 
Clinical presentation 
Classical CAH 
One study found that about 70% of those with classical CAH were SW (16). SW is the most 
severe phenotype, characterised by deficiency of both cortisol and aldosterone, and                                          
clinical presentation with life-threatening salt-losing crises early in life. Soon after delivery 
they develop severe symptoms with vomiting, hypovolemia, hypotension and pronounced 
electrolyte disturbances characterised by hyperkalemia and hyponatremia. Boys are at 
increased risk, as they are unlikely to be diagnosed by clinical examination. The increased 
production of ACTH and adrenal androgens only yield subtle hyperpigmentation and 
possibly an enlarged penis. A recently published study from UK, a country without neonatal 
screening, demonstrated that in the first months of life, most girls (77%) present with genital 
virilisation, whereas most boys (73%) present with salt-wasting crises (28). They found that 
only 6% of the girls remained undiagnosed by day 14, in contrast to 50% of the boys.  
 
Female neonatals with the SW and SV forms have severe virilisation of external genitalia due 
to androgen excess in utero, usually less pronounced in SV than in SW. Characteristic 
findings include an enlarged clitoris, partly fused labia majora and a common urogenital sinus 
20 
 
in the place of a separate urethra and vagina, whereas the internal female organs, the uterus, 
fallopian tubes, and ovaries, are normal (1). The majority of the SV girls are diagnosed 
during the neonatal period. However, some girls can be mistaken as boys, because their 
pronounced clitoris hypertrophy is interpreted as a penis. CAH is a common cause of DSD. 
Screening for CAH will result in earlier diagnosis of girls and avoid much harm to the girls 
and the parents.  
 
In older children, untreated or unrecognised CAH may result in premature puberty, 
accelerated bone maturation, and fertility problems. Untreated boys with the SV form start 
puberty and virilisation at age two-four years and can become full-grown as early as seven 
years old. This implies that these patients, and particularly the boys, are taller than their peers 
as children and lower as adults.  
 
Non-classical CAH  
The NC or late-onset form of CAH gives symptoms around puberty in females. Affected girls 
are born with normal clitoris or mild clitoris hypertrophy. The patients have sufficient 
enzyme activity to produce both cortisol and aldosterone with increased ACTH stimulation. 
The ensuing adrenal hyperandrogenism is the problem, but to a much lesser extent than in 
classical CAH. The most common presenting symptom in children is premature pubarche 
(37;38), severe cystic acne (39), accelerated growth and tall stature in early childhood (40). 
Women with NC suffer from hirsutism, menstrual disorders including amenorrhea, 
anovulation, oligomenorrhea (3), and infertility (41). Whether NC is a clinical problem in 
men is uncertain, and the majority are only diagnosed during family screening (42).   
                                                                                                                                                                               
Diagnosis of CAH 
The diagnosis is made by clinical, hormonal, genetic, and sometimes radiological 
investigations. It is important to suspect CAH in neonates with ambiguous genitalia. The 
typical clinical presentation in neonatal is a female with enlarged external genitalia, which 
could be misinterpreted as a penis. A physical examination is mandatory, that is, to palpate 
for gonads in the inguinal canals and labia or scrotum and to look for the urethral meatus. 
Karyotyping should also be done to predict the chromosomal sex. Hyperpigmentation due to 
increased ACTH could be difficult to discover in the infants if you are not primed to look for 
it. Two thirds have concomitant salt-wasting crises; however, this rarely occurs before seven 
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days of life (16). CAH also has to be suspected in neonatal males with salt-wasting crises. 
The typical electrolyte disorders are hyperkalemia and hyponatremia. To diagnose 
aldosterone deficiency measurement of aldosterone and renin is required; aldosterone is low 
and renin compensatorily high and the aldosterone to renin ratio is low (43;44). In the first 
days of life this is however difficult to interpret as plasma renin activity and aldosterone are 
elevated in many healthy infants (45). 
 
Basal serum 17-OHP is the diagnostic test; if this is clearly elevated, the diagnosis of 21-
OHD is definitive. A three days post partum 17-OHP value above 242 nmol/L is diagnostic 
of classical 21-OHD in a full-term infant (1); the normal value is less than 3 nmol/L. In 
countries with neonatal screening most of the patients will be diagnosed shortly after birth 
(see the next section). If diagnosed later in childhood or in adulthood levels of 17-OHP in the 
morning below 2.5 mmol/L and 6.0 mmol/L, respectively, effectively rule out CAH (1). 
Basal or stimulated 17-OHP above 300 nmol/L is typical for classical CAH (2). The cut-off 
values for NC is basal 17-OHP of 15 nmol/L and/or ACTH-stimulated 17-OHP of 45 
mmol/L, measured at any time of the day or any time during the menstrual cycle (1) or basal 
and/or stimulated 17-OHP level above 6 and 30 mmol/L, respectively, measured in the 
follicular phase (6) tested with high dose ACTH (250 μg). An ACTH-stimulation test can be 
done to diagnose NC, to evaluate the cortisol production, and to rule out other enzyme 
GHILFLHQFLHV,Qȕ-hydroxylase deficiency stimulated 17-OHP may be moderately elevated, 
but rarely above 40 nmol/L. Genetic analysis can be useful to confirm the diagnoses and also 
provide additional information such as prediction of the clinical course and hopefully prevent 
serious consequences (46).  
 
Neonatal screening 
Neonatal screening for CAH implies screening for the classical form of 21-OHD as NC 
displays too low levels of 17-OHP to be detected. However, occasionally, 1ȕ-hydroxylase 
deficiency can also be detected by such screening. In many countries, including the USA, 
neonatal screening for 21-OHD is an approved part of the neonatal screening programme. In 
2009, forty-nine states in the USA and at least 16 other countries screened infants for CAH, 
and at least 13 additional countries had pilot or local screening programs in 2009 (47). In 
Norway, screening commenced in 2012. The primary goals of neonatal screening for CAH 
are to prevent neonatal death from salt-wasting crises, inaccurate sex assignment in females 
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with complete virilisation, and irreversible childhood hyperandrogenism. CAH is well suited 
for screening as it is fairly common, potentially fatal, and treatable. Initial testing is easy to 
perform by analysing 17-OHP by immunoassay on dried blood-spots on the filter paper card. 
However, this assay has low specificity, yielding a positive predictive value of approximately 
1% as estimated from data from the entire USA in 2003-2007 (47), and frequent false-
positive results. The cut-off levels of 17-OHP is the main issue as too low levels will give 
many false positive tests; however, too high level will reduce sensitivity and give false 
negative tests. Most affected neonates have concentrations greater than 105 nmol/L (48). 
Other factors that limit the accuracy of the test are that the levels of 17-OHP are normally 
high at birth and decrease rapidly during the first postnatal days, and that premature or sick 
babies also have high levels. Neonatal girls have lower mean 17-OHP levels than neonatal 
boys, which slightly reduces the sensitivity of the screening for CAH in girls (49). Many 
screening programs have established reference ranges that are based upon weight and 
gestational age to improve the positive predictive values. In The Netherlands this improved 
the positive predictive value of CAH screening from 4.5% to 16 % (25). It is still not well 
documented that neonatal screening of CAH reduces mortality by identifying infants with 
severe SW before they develop adrenal crises (50). The documented effects of neonatal 
screening are earlier diagnosis in affected neonates, increased detection of males, and higher 
recorded incidence than in countries were diagnosis is based on case reports (16). Since 
Sweden started neonatal screening in 1986 they have no documented fatal event of salt-
wasting crises, the recorded incidence of CAH has increased, particularly for males. One 
quarter of the CAH girls and three quarters of the CAH boys in the Swedish screening 
program were diagnosed only by screening and would not have been detected by clinical 
investigation in the neo-natal period alone (23). 
 
Treatment 
The aim of the treatment is to replace the missing glucocorticoid and mineralocorticoid 
hormones to prevent salt-wasting crises and death, and to normalise androgens to prevent 
virilisation. Other goals are to optimise growth and development and to protect against co-
morbidities.  
 
Glucocorticoids 
Since the aim of glucocorticoid treatment in CAH is not only to replenish glucocorticoids and 
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mineralocorticoids, but also to suppress ACTH driven androgen production, the doses needed 
are often higher than in patients with primary adrenal insufficiency. Neither of the 
conventional glucocorticoid therapies satisfactorily mimics the normal diurnal cortisol 
profile, and new modes of glucocorticoid delivery have been proposed. Modified-release 
hydrocortisone (HC) tablets have been produced, which better restore the normal rhythm and 
hence might yield suppression of adrenal androgens production with lower glucocorticoid 
doses (51). Recently, cases with poorly treated CAH have been successfully controlled with 
continuous subcutaneous HC infusion (CSHI) (52-54)  a treatment previously introduced for 
patients with Addison’s disease (55).  
 
Suppression of ACTH is important in both women and men, as high ACTH levels stimulate 
growth of both testicular adrenal rest tumours (TART) and the adrenals themselves, 
sometimes with the development of myelolipomas (56;57). Adrenal myelolipomas are benign 
tumours composed of adipose and myeloid tissue. Whether high adrenal androgens are 
harmful for adult males is not known, but when the adrenal source of androgens dominates, 
the hypothalamo-pituitary-testicular axis is suppressed, resulting in sterility and infertility. 
Adults are often treated with long-acting glucocorticoids or a combination of long-acting and 
short-acting glucocorticoids. The most recent guidelines suggest that adult patients with 
classical CAH should be treated with HC or long-acting glucocorticoids (2), which is a very 
unspecific advice. In practice, adults are often treated with prednisolone (58;59); however, 
there are no studies on long-term follow-up of different modes of treatment of adults, and 
practice varies.                                                         
 
Physiological cortisol secretion rates are about 6 mg/m2 daily (60;61) and most patients have 
satisfactory control of androgen production with HC doses of 12-18 mg/m2 daily divided into 
two or three administrations (1). The latest Endocrine Society Clinical Practice Guidelines 
recommend 15-25 mg HC daily, alternatively prednisolone 4-6 mg, or dexamethasone 0.25-
0.5 mg daily (2). This approach is a trade-off between overtreating the patients, with side 
effects of glucocorticoids, or undertreating, with complications due to hyperandrogenism and 
hypocortisolism (62). In children there are more established guidelines for management 
recommending the use of short-acting glucocorticoids such as HC 10-15 mg/m2/day divided 
into three doses, to optimize growth and final adult height (63). The treatment in children also 
deals with gender assignment, genital surgery and pubertal development. In Norway 
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cortisone acetate is the drug of choice in both children and adults, as HC is only available on 
registration exemption. Cortisone acetate has to be converted to cortisol for biological 
DFWLYLW\DQGWKLVFRQYHUVLRQFDQEHLPSDLUHGGXHWRORZDFWLYLW\RIKHSDWLFȕ-
hydroxysteroid dehydrogenase type 1 and therefore perceived a less favourable alternative 
(64). However, dysfunction of this enzyme is not known to pose a problem in clinical 
practice. The latest Endocrine Society guidelines recommend against the use of stress doses 
in mental and emotional stress, minor illness, and before physical exercise (2). However 
many of our patients, perceive that extra doses in these situations are helpful and Reisch et al. 
have also recommended this (62). 
 
As in patients with Addison’s disease (primary adrenal failure) it is important to educate the 
patient to increase the glucocorticoid doses under stress such as febrile illness and surgery to 
avoid life threatening adrenal crises. Only the study by Reisch et al. has focused on this 
important issue in adult patients with CAH (62) in which few patients were equipped with 
emergency cards. The Reisch et al. recommendations to prevent adrenal crises are 
summarized in Table 5. 
 
The optimal dose and administration schedule of hydrocorticsone in critically ill CAH 
patients is unknown, but 100 mg bolus doses of HC i.v. four times daily is often used (2). 
However Charmadari et al. measured plasma cortisol concentrations after i.v. HC in children 
with CAH and demonstrated very high peak levels within ten minutes after the bolus was 
given, followed by a rapid fall thereafter (65). They concluded that critically ill patients with 
classical CAH would be best managed with a single intravenous HC bolus followed by a 
constant infusion.  
 
Mineralocorticoids  
Fludrocortisone is the only drug available as mineralocorticoid replacement. It is 
recommended that all classical CAH patients be treated with mineralocorticoids at diagnosis 
in the neonatal and early infancy period. The need for mineralocorticoids often decreases 
with age for a number of reasons. One is that serum aldosterone is high in healthy subjects at 
birth, and this could be due to low renal mineralocorticoid receptor activity (45). Another 
reason could be extra-adrenal 21-hydroxylation (35;66) being able to generate enough  
aldosterone to decrease salt loss. Another argument for using fludrocortisone are studies 
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Table 5  Practical guidelines for CAH patients to prevent Adrenal Crises (Adapted from 
Reisch et al. (62). 
1 Always carry your steroid emergency card with you. 
2 Situations that require glucocorticoid dose adjustment by yourself (triple dose of 
glucocorticoid immediately): 
a) Nausea with vomiting and diarrhoea: if no i.v. or i.m. injection is available, 
repeatedly take three times the oral dose of hydrocortisone despite 
vomiting, as some absorption of hydrocortisone takes place very quickly. 
See a physician without delay. 
b) Intercurrent illness with fever >38.5ƕ C  
3 Situations where you may benefit from glucocorticoid adjustment: 
a) Sustained psychological distress 
b) Extensive physical exercise: be cautious with glucocorticoid dose 
adjustment, as this has not been shown to be beneficial, but increase intake 
of sugar/carbohydrates (67) 
4 Other situations: extreme heat- increase water, and in particular salt intake 
5 Mineralocorticoid dose can be continued as usual, no increase of dose necessary 
6 Situations that require glucocorticoid dose adjustment by a physician: 
a) Surgical intervention 
b) Shock, severe trauma, coma, and emergency surgery 
c) Continued vomiting and diarrhoea 
 
 
indicating that all forms of 21-OHD have some degree of aldosterone deficiency (44;68) and 
that patients requiring mineralocorticoids have better height outcome compared with non-SW 
patients (69). Fludrocortisone replacement even in mild aldosterone deficiency results in 
lower glucocorticoid dose requirement and better height outcome (70). The usual daily dose 
of fludrocortisone ranges from 0.05-0.2 mg/day in adults independent of body size 
administered in the morning. Recovery from salt-wasting has been described and sensitivity 
to mineralocorticoids may vary over time. Therefore the need for continuing 
mineralocorticoid and/or salt supplementation should be reassessed regularly based on blood 
pressure, plasma renin activity (PRA), and perhaps the aldosterone to PRA ratio (44;66). 
Many patients have a large salt consumption, which could be an indication of need for more 
fludrocortisone. Additional salt supplements are given on a routine basis to maintain plasma 
sodium concentrations in the normal range in the first 6-12 months of life (1-2 g daily) (71). 
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Later additional salt intake may be needed with exposure to hot weather and patients should 
be encouraged to use salt freely to satisfy salt cravings (72) and be told that sodium salt-
intake is important for them and not harmful.  
 
Monitoring 
The glucocorticoid doses are monitored with clinical and biochemical parameters. 
Biochemical monitoring of therapy in CAH is however controversial and difficult as the 
serum hormones fluctuate with time of day and intake of glucocorticoid tablets. Hence, 
unfortunately, target concentrations are not clearly defined. The three most commonly used 
adrenal steroids for monitoring treatment are 17-OHP, androstendione and testosterone. 
Levels of 17-OHP may be elevated at night and suppressed after the morning glucocorticoid 
doses17-OHP, and displays a circadian rhythm resembling that of cortisol with nadir at 
midnight and peak in the early morning (73). However, although a random test of serum 
hormones has limited value, the therapeutic efficacy has until now been assessed by 
measurement of 17-OHP in the mornings before intake of glucocorticoid tablets (6;63;74). 
The level of 17-OHP should not be normalized because of risk of iatrogenic Cushing’s 
syndrome (signs and symptoms associated with prolonged exposure to inappropriately high 
levels of cortisol ). Thus, the recommended target range in the morning is from 12-36 nmol/L 
(1). Androstendione levels reflect the levels of adrenal androgens and should be within a 
range appropriate for the patient’s age and sex (74). Testosterone can also be a useful 
parameter, especially in women. In men, the measured testosterone levels mainly derives 
from the testicles; it may be reduced due to high glucocorticoid doses or pronounced TART  
(75). Alternative measurements for adjusting the glucocorticoid doses include 24h urine 
collection for pregnantriol, a urinary metabolite of 17-OHP, and 17-ketosteroids, which are 
urinary metabolites of androgens, or by 17-OHP time series with dried blood spots or salivary 
17-OHP day profiles (76-78). 
                      
The mineralocorticoid doses should be adjusted to maintain plasma renin activity in mid-
normal range. Nimkarn et al. suggested that the aldosterone to PRA ratio is a better marker of 
mineralocorticoid requirement (44). The clinical assessment is as important as or more 
important than the biochemical parameters. In children growth velocity and bone age are 
important. In adults weight, blood pressure, bone mineral density (BMD), amenorrhoea and 
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signs of both iatrogenic Cushing’s syndrome and undertreatment of glucocorticoids with 
fatigue and adrenal crises should be assessed (2;62).  
 
Outcome 
Studies of clinical outcome in adult CAH patients over 30 years of age, and especially men, 
are sparse and the cohorts often small, with the exception of two larger studies published 
recently (59;62). The studies often originate from single treatment centres. No studies on 
mortality or serious outcomes as cardiovascular disease have been published for this patient 
group. No clear consensus exists for the medical management of adults with CAH although 
the Endocrine Society Guidelines appeared in 2010 (2). During the research period several 
actual studies appeared with the outcomes we were looking for, and published either before 
or after our papers. These references are marked with italic.  
 
Health-Related Quality of Life (HRQoL) 
Data on HRQoL in CAH are diverging and before the start of this study; less than five 
surveys included adult CAH, and only one included men. Some studies revealed better and 
some worse HRQoL than reference populations. The CAH population is heterogeneous, 
ranging from patients with a traumatic childhood with intersex issues, girls with severe 
virilisation who have never been on a public beach, to the patients who were diagnosed 
prenatally and treated in a specialist centre with excellent results.  
 
Another issue is that many studies have shown that girls with CAH have a masculinized 
behaviour, that is, tomboy play behaviour, aggressive manners and altered spatial perception 
(79). Gender-atypical behaviour is also seen in adult age, such as homosexuality, choice of 
typical ‘male’ professions and leisure activities (80). Behavioural masculinisation in girls 
with CAH is believed to result from the exposure of the brain to high levels of androgens 
during fetal development (81). It may also be assumed that the younger CAH population has 
received better treatment than the older population and that introduction of neonatal screening 
in many countries contributes to improvement in HRQoL. Two recent larger studies of 
younger men and women with classical CAH from UK and Germany showed significantly 
impaired HRQoL (59;82). Several smaller studies including only women support these 
findings (83-85). No difference from controls was seen in two other reports in women 
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(86;87). In contrast, a Finnish study with men and women reported significantly better 
HRQoL in the CAH patients than in the normative controls (88).  
 
Fertility 
Female fertility 
Low pregnancy rates among females with CAH have been reported, especially among 
women with the SW form (89-92). Many factors could contribute to this, for instance 
congenital genital malformations with masculinization of the external genitalia and an 
inadequate introitus (89). Other causes may be directly hormonal under conditions of 
undertreatment; high adrenal androgens result in virilisation and suppression of gonadotropin 
secretion from the pituitary, leading to oligo- and amenorrhoea and anovulation (90). 
Moreover progesterone hypersecretion has a negative effect on endometrial receptivity. 
Overtreatment with glucocorticoid also suppress gonadotropins (93). Higher frequencies of 
polycystic ovaries are also reported in CAH, which might inhibit ovulation (94). 
Homosexuality and single status is more common among CAH women than in the 
background population. Homosexuality is reported at 20% in two different studies vs. 1.6-
5.7% in the control groups (80;95). In the study by Frisén et al. homosexuality was most 
common in the patients with severe CYP21A2 mutations, 50% in the null genotype group 
(N=14), 30% in the I2 splice group (N= 15), and 5% in I172N (N=25) in contrast to 2% in 
their controls (80). Four studies reported pregnancy or live birth rates at 20-26% as opposed 
to 65-76% in the normal population (90;92;95;96). The reported pregnancy or live birth rates 
among women with SW were very low at 1/9 (91) and 1/40 (89). However, normal 
pregnancy rates were reported in a recent study including 106 women with classical CAH (81 
SW and 25 SV), when pregnancy rates were calculated as successfully attempted conceptions 
(97). Twenty-five women (23.6%) considered motherhood; nine were SW. Twenty-three had 
actively tried conception of whom 21 (91.3%) achieved 34 pregnancies; hence, the authors 
stated that the pregnancy rates were similar to the normal population in those planning 
pregnancy (95%). They found similar pregnancy rates in SW (89%) and SV (93%). Thus, a 
pertinent question seems to be why CAH women do not want to become pregnant?  
 
In the literature only a total of 150 pregnancies or live births have been reported in women 
with classical CAH and the health of the children are considered good (90;95;97-99). Prenatal 
treatment with dexamethasone is effective in reducing virilization in CAH-affected girls and 
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is considered safe by many groups (100). Dexamethasone is not inactivated by placental 11 
ȕ-hydroxysteroid deydrogenase type 2 and traverses placenta; however, current Clinical 
Practice Guidelines classifies this treatment as experimental and states that larger studies are 
needed to evaluate its risks and benefits (2). In Sweden, a study is ongoing on prenatal 
dexamethasone treatment in pregnancy, which has included 30 women over the last ten years 
(101)  . 
 
Male fertility 
Data on fertility in men with CAH are conflicting, and few data exists on paternity. Urban et 
al. found normal fertility in 18 of 20 patients, as evaluated by paternity and/or sperm count 
(102) whereas Jääskeläinen et al. found significantly reduced male birth rate in 29 patients 
compared with age-matched controls (child rate was 0.07 vs. 0.34 (p<0,001)) (103). TART, 
as described above, may result in oligoazoospermia or Ledyig cell failure, and have been 
associated with reduced male fertility (104). Other factors could be overtreatment with 
glucocorticoids, hereditary or psychological factors. Stikkelbroeck et al. also reported an 
association between low gonadotropines and high levels of adrenal androgens (104). Reisch 
et al. found that all the 22 males studied (15 SW and 7 SV) had pathological semen analysis 
and in several men, hormonal control parameters suggested hypogonadism, with 
glucocorticoid overtreatment as probable cause of poor semen quality (105). Other factors, 
such as social status or sexual preference have not been investigated in adult males, with the 
exception of Falhammar et al.’s recently published study (106), which showed reduced 
fertility compared with national data (0.9 ± 1.3 vs. 1.8± 0.5 children/father ratio) in a cohort 
of 30 CAH males, aged 19-67 years. There were no major differences in social and sexual 
factors between patients and controls, apart from more fecundity problems, particularly in the 
I172N group vs. null and I2splice groups. Fecundity problems were defined as attempting to 
become a father for more than one year.              
 
Tumours 
Adrenal tumours and adrenal size  
It is well known that CAH results in large adrenals (as the name implies), caused by chronic 
increased ACTH stimulation of the adrenal cortex. Whether ACTH hypersecretion also cause 
tumour growth is uncertain. Few studies have determined the prevalence and size of adrenal 
hyperplasia in adult CAH patients or looked for adrenal tumours. Reisch et al. recently found 
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significantly higher combined adrenal volume in male CAH patients (median 9.3 ml (range 
3.2-124.5)) than in controls (7.4 ml (5.5-10.8 ml)), and documented an association between 
total adrenal volume and hormonal control. They found adrenal nodules in 19 of 26 (73%) 
males with CAH in contrast to 3 of 26 (11%) controls (56). Jaresch et al. demonstrated 
increased frequency of adrenal incidentalomas in heterozygous CYP21 mutation carriers 
(nine of 20 (45%)), and in SV (18 of 22 (83%)) (107). Conversely, series of adrenal 
incidentalomas have been tested for germline CYP21 mutations, showing diverging results 
(108-110). In summary, adrenal tumours seems to be common in CAH, but that CAH is not a 
common cause of adrenal tumours.  
 
Testicular adrenal rest tumours (TART) 
The presence of TART in CAH was first described in 1940 (111). TARTs are well-defined 
hypoechoic lesions in the testicle near the rete testis. They are benign and often bilateral, and 
arise from adrenal-like cells that migrate into the testis in foetal life. These aberrant adrenal 
cells are most likely stimulated by ACTH (112) and probably disappear if not stimulated 
(113). TART cells express &<3ȕand CYP21 activities and have receptors for both ACTH 
and angiotensin II (112). Thus, undertreatment with glucocorticoids and mineralocorticoids 
can stimulate tumour growth (112). Long standing TART can lead to obstructive 
azoospermia and irreversible damage of the testicular parenchyma with fibrosis and 
peritubular hyalinization, ultimately leading to gonadal dysfunction and infertility (75). 
TART may also have paracrine effects via steroids produced by the tumour cells (114) which 
could be toxic to the germ cells (104;115). High doses of glucocorticoids could possibly 
reduce tumour size and increase fertility (116). The prevalence of TART in CAH males is 
reported between 0 and 94% (102;104); confounding factors being methods of tumour 
detection, experience of the investigator, and patient selection. The true prevalence of TART 
in an unselected CAH population is unknown. The localisation of the tumours within the rete 
testis renders them difficult to identify by clinical examination and only tumours larger than 
two cm are detectable by palpation (115). Avila et al. diagnosed TART in 12 of 42 (29%) 
patients, of whom 10 had no palpable testicular abnormalities (117). Ultrasound or MRI is 
therefore required to detect TART (115). Whether this should be a routine investigation in 
CAH males is arguable as the consequence of detecting a small TART is uncertain. 
Ultrasound and MRI are considered equal modalities for detecting TART (118;119), however 
31 
 
no gold standard exist for diagnosis. Ultrasound is often preferable as it is easily available, 
quick and inexpensive.  
 
 
Ovarian tumours 
As males with CAH could develop TART the women could perhaps develop ovarian adrenal 
rest tumours. However, these are exceedingly rare. Only ten cases have been reported; five of 
them had CAH due to 21-OHD, three with other adrenal enzyme deficiencies and two cases 
in women with Nelson’s syndrome (120), which is characterised by enlargement of an 
ACTH-producing pituitary adenoma after adrenalectomy. Stikkelbroeck et al. searched for 
ovarian adrenal rest tumours  in 13 female CAH patients with both ultrasonography and 
magnetic resonance imaging (MRI), but did not detect any (121). 
 
Clinical Characteristics 
Height  
Patients with CAH often reach a final adult height significantly below their parentally 
determined target height and they are shorter than the normal population (59;122;123). The 
UK study showed that the CAH men were 14 cm shorter than the men in the general 
population, 162 vs. 176 cm; corresponding figures for women were 10 cm shorter, 152 vs. 
162 cm. Excess of androgens results in rapid linear growth with premature epiphyseal fusion 
and reduced final height. Overtreatment with glucocorticoids also suppresses growth, 
especially if potent longer-acting glucocorticoids such as prednisone or dexamethasone are 
used (123). Bonfig et al. recommend that the dose of HC should not exceed 17 mg/m2/day to 
give optimal pubertal growth (124). A recent review and meta-analysis from 35 eligible 
studies concluded with reduced final height in both sexes at -1.38 SDS. The SD score (SDS) 
is a normalised SD that expresses height differences in terms of the SD for height in the 
reference population. They found no correlation between height and age at diagnosis, gender, 
type and dose of glucocorticoids, nor age at onset of puberty. Mineralocorticoid users had a 
better height outcome in comparison with the non-users (69). The meta-analysis also suggests 
improved outcome in height over the last years due to better treatment. An older meta-
analysis from 2001 showed more reduced final height in males and females compared to mid-
parental height at -1.57 SDS and -1.24 SDS, respectively (125). These findings indicates that 
appropriate treatment with glucocorticoids and mineralocorticoids is important to achieve 
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optimal adult height in patients with CAH. Furthermore, newer reports have shown improved 
height outcome with additional treatment with growth hormone alone or growth hormone in 
combination with LH releasing hormone, but this is not an established therapy (126).  
 
Body mass index (BMI) and body composition 
Glucocorticoids increase fat mass and reduce lean body mass (127), whereas androgens have 
the opposite effects (128). Overtreatment with glucocorticoids might even induce serious 
side-effect such as Cushing’s syndrome with weight gain, striae, buffalo hump, facial 
plethora and proximal myopathy. Many studies have reported increased BMI in children, 
adolescents and adults with CAH (59;129;130). The largest study from the UK including 62 
PHQDQGZRPHQVKRZHGWKDWRIWKHPHQZHUHREHVH%0,NJP2) vs. 22% in 
the general population; in women the corresponding numbers were 52% vs. 27% (59). The 
authors proposed that both glucocorticoid overtreatment and mineralocorticoid 
undertreatment could explain these findings. Völk et al.’s report on overweight in children 
and adolescents with CAH indicated that glucocorticoid dosage, chronologic age, premature 
bone age maturation, and parental obesity contributed to high BMI, whereas birth weight and 
length, serum leptin levels, glucocorticoid used, and fludrocortisone dosage did not (129). It 
has been debated whether fat mass is a better indicator of body fat in CAH than BMI, which 
is systematically skewed due to short height. Furthermore, increased muscle mass due to 
androgen excess in women can overestimate body fat if BMI is used (58). Five studies have 
investigated body fat in adults, two in both sexes (131;132), two in women (58;133), and one 
in men (134). The two studies in men and women showed increased fat mass in males but not 
in females with CAH (131;132), of which one showed no significant difference in BMI (131). 
Two Swedish studies that included only females showed diverging results. The first, which 
included 13 females, showed significantly higher fat mass than the controls, 24.9 vs. 16.2 kg 
(mean). The mean age in these women was 23.9 years (range 20-29). The other study in 55 
females did not show any differences in fat mass or BMI compared with controls. These 
patients were slightly older, with a median age of 30 years (range 18-63). Finally the male-
only study subgrouped the participants below and above 30 years. The older had significant 
higher fat mass than the controls, 8.2 vs. 5.9 kg/m2 (mean), whereas the younger group were 
not different form controls.  
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Bone mineral density (BMD) and fractures 
Glucocorticoid therapy may reduce BMD in CAH, whereas androgens could increase BMD 
in men (128). Whether   higher adrenal androgens in females increase BMD is uncertain, but 
one small study supports this (135). Glucocorticoids accelerate reduction in bone mass by 
inhibition of osteoblast activity, stimulation of osteoclast activity, inhibition of intestinal 
vitamin D dependent calcium absorption, and increase in the renal excretion of calcium 
(136;137). Chronic treatment with glucocorticoid for various disorders induces osteoporosis, 
which typically occurs within the first six months of treatment, followed by slower but steady 
loss of bone with continued use (136). The incidence of osteoporosis and fractures is related 
to the doses and duration of glucocorticoid therapy (136). Prolonged glucocorticoid therapy, 
even in replacement doses, may lead to reduced BMD, but it is uncertain whether 
glucocorticoid replacement therapy affects bone mass in patients with CAH. Previous reports 
in adult patients revealed variable results. The majority of studies showed reduced BMD 
(59;118;138-142); others showed no impairment (130;131;143;144). Certainly, other factors 
such as genetic predisposition, premature puberty, elevated adrenal androgens and 
hypogonadism also impact on BMD. To our knowledge only one study adressed fractures; 
among 61 CAH women; 31 fractures occurred in 18 individuals as opposed to two fractures 
in two of the 61 controls (138).   
 
Cardiovascular risk factors 
As mentioned above, clinical reports in CAH patients above 30 years are few and therefore 
no reports exist on prevalence of coronary or cerebral vascular disease.  
 
Dyslipidaemia 
Lipid profiles in adult CAH patients have only been measured in a few studies and the 
majority did not show any difference from controls (58;134;145;146). Mooij et al. 
investigated 12 men and 15 women (30.2± 8.0years, mean± SD) with CAH and found equal 
levels of total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides, but 
significantly higher levels of high-density lipoprotein (HDL) cholesterol than in 27 age, sex 
and BMI matched controls (146). Falhammar et al. investigated women and men separately, 
and found no difference between CAH and controls, however the women above 30 years of 
age had higher HDL to LDL ratios and a tendency towards higher HDL-cholesterol than 
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healthy controls (58;134). The larger UK study showed that many adult men and women with 
CAH had dyslipidemia, but lack of controls renders the interpretation difficult (59).  
 
Insulin resistance 
In general, glucocorticoid excess can cause insulin resistance and increase in both fasting and 
postprandial glucose levels in patients without pre-existing diabetes mellitus; however, the 
development of diabetes mellitus in a patient with initially normal glucose tolerance is 
uncommon (147). No report exists on the prevalence of diabetes in adults with CAH except 
Swedish observations of increased prevalence of gestational diabetes (90). Three of 14 with 
CAH (21%) compared with none of 41 controls, had a history of gestational diabetes 
(P=0.026). The reported frequencies of gestational diabetes from the general population were 
1.4 - 4%. Two studies found increased insulin resistance in classical CAH (145), but not in 
NC females without glucocorticoid treatment (148). 
 
Blood pressure 
Studies of blood pressure in adult CAH patients show diverging results. Two studies by 
Falhammar et al. measuring either single blood pressures (58) or 24h ambulatory blood 
pressures (134) found values similar to controls. In contrast, Mooij et al. found elevated 
systolic and diastolic 24h ambulatory blood pressure in 27 adults with 21-OHD of both sexes 
compared with BMI matched controls (146). Arlt et al. recently found significantly increased 
diastolic blood pressure in 102 female CAH patients compared with national data in the UK, 
but no difference in systolic blood pressure. The 61 male CAH patients in that study had 
slightly but significantly lower systolic blood pressure than the population-based norm (59).  
 
Intima-media thickness 
Increased intima-media thickness (IMT) has been described a risk factor of cardiovascular 
and cerebrovascular disease (149). Sartorato et al. investigated 19 CAH patients (ten  
females, nine males; 28±3.5 years) and reported increased IMT in CAH patients (145). No 
correlations between IMT and cumulative glucocorticoid doses or androgen levels were 
observed. 
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Vocal pathology      
The Swedish group demonstrated voice problems in females with CAH (150), who rated 
higher agreeement than controls to the statement “my voice is a problem in my daily life”. 
The women speak with lower mean, lower minimum and lower maximum frequencies than 
controls.         
 
Mortality                                                                                                                                                              
Only data on increased perinatal mortality exists. Before 1950 when the glucocorticoid 
tablets became available, neonates with SW died in the neonatal period due to lack of 
glucocorticoids and mineralocorticoids, which indicates that the oldest living patients with 
SW are approximately 63 years. There is no data on mortality in adults CAH patients. 
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AIMS OF THE STUDY 
 
When we initiated our studies in 2006 no publications or information about CAH in Norway 
existed. World-wide, only a few population-based studies had been published on adult CAH, 
and hardly any including males. However, over the project period some larger studies have 
been published from the UK (59), Germany (82), and Sweden (58;106;134;138;151).  
 
Our main goal was to collect and describe the burden of CAH in adult life in Norway. The 
specific aims were to describe: 
 
x (SLGHPLRORJ\RI&$+LQ1RUZD\3DSHUǿǿ 
x *HQHWLFVDQGFOLQLFDOFKDUDFWHULVWLFV3DSHUǿ9 
x HRQoL DQGZRUNLQJDELOLW\3DSHUǿǿ 
x 7HVWLFXODUDQGDGUHQDOWXPRXUVLQ&$+3DSHUǿǿǿ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METHODS 
 
Subjects  
Identification 
To identify all patients in Norway over 18 years of age with classical CAH we searched in 
electronic diagnosis registries at the six university hospitals in Norway that have adult 
endocrine units. The diagnosis registries had start dates ranging from 1972 to 1999. The 
search criteria were age 18 years or more on 1.1.2007, and the International Classification of 
Diseases (ICD) codes 255 (ICD 8 and 9) and codes E25 and E27.9 (ICD 10), that is, 
adrenogenital syndromes and unspecific adrenal diseases. Furthermore, endocrinologists at 
all the regional hospitals were contacted and requested to report CAH patients. All 
practitioners in the country were approached in an advertisement in The Journal of the 
Norwegian Medical Association, on the web pages of the Norwegian Society for 
Endocrinology, and in the Journal of the Norwegian Addison’s Association, which organizes 
patients with CAH. 
 
The CAH diagnosis was verified by endocrinologists by scrutiny of original medical records 
in all the patients, including data on genital examination, symptoms at presentation 
(hypotension, nausea and electrolyte abnormalities), levels of adrenal steroids, and, if 
investigated, genetic analyses. We identified 115 patients uniformly distributed throughout 
Norway. One hundred and four had 21-OHD; of these, 101 were alive. Five patients were 
registered with 17-ĮK\GUR[\ODVHGHILFLHQF\WKUHHZLWK-ȕ-hydroxylase deficiency, and two 
with 3-ȕ-dehydrogenase deficiency and one unknown.   
 
Most likely we identified nearly all adult CAH patients who have been provided specialist 
endocrine care. Of the 104 identified patients with 21-OHD, 65 were women and 39 were 
men and nine of them were identified via endocrinologists at regional hospitals. All the 
registered live patients with 21-OHD were invited to participate in a questionnaire survey. 
Altogether, 72 of 101 patients agreed to participate (47 females), yielding a response rate of 
72% (one patient was not competent to answer questionnaires). The subjects had a median 
age of 38 years (range 18-72) (paper II). The patients were classified clinically as SW if they 
had signs of severe mineralocorticoid deficiency during the first three years of life, that is, 
hypovolemic shock, vomiting, low serum sodium, or high serum potassium, and if the term 
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salt-loser was used; in girls with the presence of virilisation of external genitalia. SV was 
diagnosed in females with virilisation of external genitalia, and in men with signs of 
peripheral precocious puberty before age six years, and no signs of mineralocorticoid 
deficiency.  
 
In the clinical studies (paper III and IV), which were conducted in 2008 - 2010, six patients 
dropped out and two women were withdrawn as we could not find any mutation in the 
CYP21A2 gene and in retrospect the 21-OHD diagnoses were uncertain. In the X-ray study 
(paper III) 62 patients participated, but two more patients were withdrawn, one due to 
claustrophobia and one was excluded due to previous adrenal surgery. In the last study, paper 
IV, 64 patients participated.  
 
Data collection 
Each participant completed a registration form covering medical history, diagnosis, treatment 
and working ability. The form also included questions about marital status, number of 
children, and symptoms and interventions related to sex hormone disturbances. Further, they 
completed the Short Form 36 (SF-36) and Quality of Life Scale (QOLS) questionnaires (see 
next page). Non-responders were reminded with a second letter.  
 
In the clinical studies, the patients were examined at four University Hospitals, according to a 
standardized protocol including measurements of height, weight, waist and hip 
circumference, and supine blood pressure measurements, DXA with BMD and body 
composition, ultrasound of the testicles, adrenal CT and blood samples. Blood samples were 
collected in the morning after an overnight medication fast. Blood samples were frozen and 
all the hormonal analyses were collectively performed at the Hormone Laboratory at 
Haukeland University Hospital. The radiological and DXA investigations were performed at 
four University Hospitals. 
 
Controls  
We did not collect our own control group, and instead chose to use normative national data as 
comparison for the HRQoL data (152;153). Data concerning fertility and social parameters 
were compared with data from Statistics Norway (http//:www.ssb.no). An age-matched 
control population for evaluations of height, weight, waist-hip measurement, blood-pressure, 
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HDL-cholesterol, ALAT and calcium was drawn from the third North-Trøndelag Health 
Study (HUNT) in 2006-2008, which included clinical investigations of 23702 women and 
12966 men between 18-72 years of age (154). The Lunar database was used as reference for 
BMD and fat mass measurements; a previous study demonstrated that BMD in the femur and 
total body of the subjects in this database were comparable with the general Norwegian 
population (155). The biochemical analyses were compared with established reference 
values.  
 
The Regional Ethics Committee of Western Norway and the Data Inspectorate of Norway 
approved the study. The study was performed according to the Helsinki Declaration. 
 
Health-Related Quality of Life  
We assesed HRQoLwith the Short Form-36 (SF-36 form) (156), which is known and 
validated worldwide, and used in many different clinical settings. Normative data is available 
from the general Norwegian population (153). The SF 36-questionnaire comprises 36 items; 
the responses are transformed into eight subscales, namely, perception of physical 
functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general 
health (GH), vitality (VT), social functioning (SF), role limitations due to emotional 
problems (RE) and mental health (MH) (156). PF, RP and BP primarily measures physical 
health, whereas GH and VT are sensitive to both physical and mental health (157). Higher 
scores are favourable.                                           
 
No disease-specific questionnaire for CAH is available. We chose to include the Quality of 
Life Scale (QOLS) in the survey (158). This questionnaire is a 16-item, domain-specific 
instrument, which measures an individual’s overall satisfaction with life in different areas not 
usually included in health-related QOL instruments, such as independence, material comfort, 
work satisfaction, recreation, etc. The QOLS has been used in both cross-sectional and 
randomised controlled studies of different patient groups with chronic diseases (158), tested 
for validity and reliability (159), and normative reference ranges for the general Norwegian 
population exist (152). The response is scored by adding up the items to obtain a total index 
(min 16–max 112); higher scores are favourable.  
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Fertility 
The participants reported number of childbirths, if they had been investigated or treated for 
infertility and in women, menstrual disorders. Expected birth rates for the women were 
estimated from the birth rates of the population cohorts of each of the patients (Statistics 
Norway: http://www.ssb.no). The standardised incidence ratio (SIR) for birth was calculated 
as the ratio between the number of observed and expected children in the patient group. 
 
Clinical chemistry  
We measured sodium, potassium, glucose, HbA1c, cholesterol, HDL, triglycerides and 
alanine aminotransferase (ALAT) by the various University Hospital laboratories. The LDL 
concentration was calculated based on total and HDL cholesterol measurements.  
 
Hormone assays and bone markers 
All the hormonal and bone markers analyses were collectively performed at the Hormone 
Laboratory at Haukeland University Hospital. ACTH, androstenedione, 
dehydroepiandrostenedione (DHEAS), parathyroid hormone (PTH), insulin C-peptide, LH, 
FSH and testosterone were analyzed with chemiluminescent immunometric assays by 
Immulite 2000 (Siemens, Surrey, UK). The ACTH, Insulin C-peptide, LH, FSH and PTH 
assays are solid phase two-site assays, whereas competitive assays were used for 
androstenedione, DHEAS and testosterone. 17-OHP was measured by a RIA-method 
(Siemens). The Gamma Coat [125 I] Plasma Renin Activity Radioimmunassay Kit was used 
for the quantative determintation of plasma renin activity by the radioimmunassay of 
generated angiotensin I (DiaSorin, Minnesota, USA). Aldosterone was measured by Coat-A-
Coat Aldosterone, a solid phase 125 I radioimmunassay designed for the quantitative 
measurements of aldosterone levels in unextracted serum (Siemens, DPC, Los Angeles, 
USA). Serum 25-hydroxyvitamin D was analysed by an isotope dilution tandem mass 
spectrometry method (Applied Biosystems/MDS Sciex, Foster City, CA, USA). Osteocalcin 
(intact and N-terminal fragment) was analysed with an ELISA assay from Nordic Bioscience 
Diagnostics (Herlev, Denmark). Interassay variation was below 11.2% for all the hormone 
analyses, and well below 10% for most of the analyses. 
 
CYP21A2 genotyping 
The gene analyses were performed by one laboratory technician and researcher (IB). DNA 
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isolated from peripheral blood lymphocytes was used for the genetic analysis. Mutations in 
the CYP21A2 gene were identified by direct DNA sequencing and deletions were determined 
by real time polymerase chain reaction (PCR). Primers used for the PCR and sequencing 
reactions have been described previously (160-162). The CYP21A2 gene was amplified in 
two different fragments, with the first primer pair selected in the promotor region and in the 
exon 6 cluster region (fragment 1), and the second primer pair in the exon 3, 8bp deletion 
region and 170 bp posterior to exon 10 (fragment 2). These specific amplifications were done 
to distinguish the pseudogene CYP21P from the active gene CYP21A2. Sequencing data were 
aligned to the CYP21A2 sequence (http://www.ncbi.nlm.nih.gov/nuccore/M12792). 
 
Copy number of the CYP21A2 gene was determined by an assay adapted from a method by 
Parajes et al. (162). A 132 bp fragment extending from exon 3 to intron 3 of the CYP21A2 
gene was amplified by duplex Taqman real-time PCR, and DSP (Desmoplakin) was used as a 
reference gene (163).  
 
Ultrasound of the testicles 
Testicular ultrasonography was performed or evaluated by four experienced radiologists in 22 
of the 23 male 21-OHD patients using high-resolution 12 mHz or 8 mHz transducers. One 
patient had had his testicles removed and ultrasound was not applicable. Measurements of 
testicular size were made from frozen images on the local ultrasound machines, and copied to 
CDs, which were sent to the central unit and read by one observer (JR). Testicular and 
tumour volumes were calculated by US using the ellipse formula: V = L x W x D x 0.52, 
where V is the volume (ml), L maximal length (cm), W maximal width (cm), and D maximal 
depth (cm), according to Martinez-Aguayo et al. (164). Testicular size was also estimated 
with an orchidectometer for comparison with published normative data (165).  
 
Adrenal CT 
Somatom (Siemens, Erlangen, Germany), Brilliance 64 (Philips, Cleveland, OH, USA) and 
Aquillon (Toshiba, Tochigi, Japan) CT machines were used. The CT-protocol included three 
series; before intravenous contrast media and 60 sec and 15 min after intravenous contrast 
media was given. The following imaging parameters were used: collimation 6.4 mm, section 
thickness 3 mm, pitch 1.4, 120 kVp  and 180 mA. Two different contrast media, iodixanol 
(Visipaque 320 mg/ml) or iohexol (Omnipaque 350 mg/ml) were used. The amount of 
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contrast (80-160 ml) was calculated on basis of the patient’s weight. All CT series covered 
the region of both adrenal glands, starting cranially. The images were saved at the local 
radiological department, copied to CDs and sent to a central reading unit where one observer 
(JR) with 20 years’ experience in adrenal imaging, assessed all the CT-examinations. Images 
were stratified as normal adrenals (limb junction <8 mm and limbs <5 mm), hyperplasia 
OLPEMXQFWLRQ!PPDQGOLPEV!PPDQGK\SRSODVLDOLPEVPPDOOPHDVXUHGLQ
axial plane according to Vincent et al. (166). Myelolipomas were diagnosed when a tumour 
had focal areas of negative attenuation values <-30HU signifying fat (167). 
 
Body composition, BMI and BMD 
Total and regional body fat, lean mass, total body, femoral neck and lumbar spine (L2-L4) 
were measured by DXA in 64 patients. Three study sites used Lunar scanners and one used a 
Hologic scanner. An earlier Norwegian study did not find significant difference between the 
Lunar compared with the Hologic scanner tested with phantom measurement (168). Lean and 
fat mass were also adjusted for body height (kg/m2) to compare with the Swedish data. BMD 
is expressed by Z-scores, representing age and gender-adjusted SDS presented with 95% 
confidence interval (CI). Osteopenia was defined as BMD T-VFRUH-1 to -2.5 and 
osteoporosis as BMD T-VFRUH-2.5, WHO criteria from 1994. BMI was calculated (kg/m2). 
 
Blood pressure 
Blood pressure was measured in the supine position, whereas the blood pressure in the 
normal population (HUNT) had been measured in the sitting position. Change from the 
supine to the sitting position in normotensive patients usually do not alter the systolic blood 
pressure, whereas the diastolic blood pressure rises by 5-10% (169). 
 
Statistics 
Descriptive statistics 
The results are given as mean and standard deviation (SD), or with 95% confidence interval 
(CI) when comparing with published control data (papers II, and IV); the parameters were 
considered statistically significantly different if the CIs of the patients and the control group 
did not overlap. Descriptive data or data not considered normally distributed are presented as 
median and range (paper III). 
 
43 
 
Hypothesis testing 
The majority of the statistical analyses involve comparison between patients and a control 
population. The null hypothesis is that the difference in the parameter of interest is zero. The 
null hypothesis is rejected if the probability of the actual finding is small, that is, by 
convention P<0.05. In paper II we have a cohort of 72 patients and in paper IV 64 patients 
and we used two sample T-test for the descriptive data included SF-36 results for comparison 
between two groups. The Mann-Whitney U-test was used to compare two groups when 
variables were not normally distributed, such as comparing adrenal and testicular size 
between the 21-OHD forms and sex (paper III) and comparing fat mass, blood pressure and 
biochemical values between sex and phenotypes (paper IV). QOLS and adrenal size were 
compared with published CIs in the general population (153;166). In paper IV biochemical 
values were compared with the reference values and body composition was compared with 
the percentage fat distribution given in the Lunar database. Fischer’s exact test was used to 
test the frequencies of adrenal tumours and TART in the SW and SV groups. 
 
Correlations and regression 
Another common statistical analysis is to study the relation between two variables within a 
group of subjects. We used the non-parametric Spearman’s rho (R) for the correlations 
between adrenal and testicular size and hormone levels (paper III), and height, BMI, age and 
hormone levels (paper IV). Multiple linear regression analysis was used for SF-36 scores to 
investigate age and gender as independent variables; and for analysis of height, BMI, fat 
mass, blood pressure, vitamin D, androgens and 17-OHP levels, with age and glucocorticoid 
doses as independent variable. 
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SUMMARY OF THE  RESULTS 
 
3DSHUǿ 
3DSHUǿLVDFDVHUHSRUWRIWZRDGXOWPHQZLWKXQWUHDWHG-OHD, who both had incidentally 
discovered large adrenal myelolipomas. We postulated that prolonged excessive ACTH 
stimulation might contribute to the growth of adrenal tumours. These two cases sparked our 
research interest in CAH and the current research project.  
 
3DSHUǿǿ 
3DSHUǿǿLVDQHSLGHPLRORJLFDOTXHVWLRQQDLUH-based survey of classical CAH due to 21-OHD 
in Norway, including subjective health status, working ability and fertility. We identified 104 
adult patients (101 alive) with 21-OHD, of whom 63% were female. This yielded an overall 
incidence at 1/20 000 live births, and an estimated incidence for girls at 1/16 000. Seventy-
two patients (72%) agreed to participate in the questionnaire survey (median age 38 years 
(range 18-72); 47 women and 25 men), of whom 40 classified as SV and 32 as SW. All the 
SF-36 scales were significantly impaired, most pronounced for general health and vitality 
perception. Subgroup analysis did neither show differences between the sexes, nor between 
SW and SV. Nineteen percent of the patients reported that they received disablement 
benefits, as opposed to ten% in the general population. The disabled patients had significantly 
lower scores in all the SF 36 items compared with the non-disabled patients. The female 
patients were more often single than the general female population, and they had only 21% of 
the expected number of children; fewest children were observed in the SW group. The male 
patients had significantly more children than the females and we found that the childless 
fraction of CAH males over 45 was roughly the same as in the general population, that is, 
about 20%. 
 
3DSHUǿǿǿ 
PapeUǿǿǿLVDVWXG\WRGHWHUPLQHDGUHQDOVL]HDQGWKHIUHTXHQF\RIDGUHQDOWXPRXUVLQDGXOWV
with 21-OHD and the frequency of TART in the males, and to investigate the correlation 
between such tumours and sex, disease categories, and hormone levels. Nine adrenal tumours 
were detected in seven of 62 patients (11%) (bilateral in two); four were myelolipomas and 
one a phaeochromocytoma. Seventeen (27%) had normal adrenal size, whereas 36 (58%) had 
persisting hyperplasia, and seven (11%) adrenal hypoplasia. Abnormal adrenals were more 
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common in SW than in SV. TART occurred exclusively in SW, and was present in eight 
(57%) of these 14 men. Testicular volumes in the males were smaller than normative data. 
Morning ACTH and 17-OHP levels correlated positively with adrenal dimensions and 
frequency of TART. 
 
3DSHUǿ9 
3DSHUǿ9VXPPDULVHVWKHJHQHWLFDQWKURSRPHWULFDQGPHWDEROLFIHDWXUHVLQ1RUZHJLDQ
adult patients with 21-OHD, who were assessed by one of the investigators at one of the 
University Hospitals. We identified four novel and plausibly disease-causing CYP21A2 
mutations. Gene deletions/conversions (42% of alleles), the splice mutation I2 splice (23%) 
and point mutation I172 N (22%) were common. The genotype corresponded to clinical 
phenotype in 92% of the patients. The prevalence of osteopenia was 44% in males and 29% 
in females. Both men and women had normal BMI, but markedly increased fat mass 
compared with the normal population. Diastolic blood pressure was higher than normal. 
Thirty-nine percent of the women had testosterone levels above the normal range; 13% of the 
men had testosterone levels below normal. Reduced final height was more pronounced in 
men (median –11.2 cm, -1.77 SDS) than in women (-6.3 cm, -1.07 SDS). 
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GENERAL  DISCUSSION AND FUTURE PERSPECTIVES 
 
My interest in this field started after a consultation with a 55 years old CAH male with a large 
adrenal tumour considered to be a myleolipoma, who had refused treatment with 
glucocorticoids since puberty. As I am writing this thesis, a colleague just diagnosed SV in a 
70 years old man, who was hospitalised due to abdominal pain. CT of the abdomen showed a 
three cm large adrenal tumour and the surgeon asked for an endocrinological evaluation. 
Paper I illustrates the importance of medical case reports as a gateway to clinical research. 
Case reports may expand the general medical knowledge as they permit discovery of new 
diseases, collection of rare diseases and unexpected effects. They can provide new ideas and 
hence initiate original research in medicine.    
 
Epidemiology and subjects 
We found 104 adult patients with 21-OHD distributed across Norway after our intensive 
effort to identify all the adult CAH patients in Norway. We believe that we have identified 
the majority of those diagnosed before 1990. We expected to find 170 patients based on an 
estimated incidence of 1/15 000 (16). However, the prevalence and incidence in Norway was 
unknown until now. Accurate figures will only be available when the results from the 
neonatal screening programme for CAH becomes available in the years ahead.   
 
We assume that our study participants are representative for the identified CAH patients as 
the distribution of sex, age, disease category and geographic distribution were almost similar 
in these population sets. Another important aspect is that our study participants are recruited 
from an unselected population and not a single specialist centre. In comparision the recent 
UK study identified only 5% of the expected CAH population and only 54% of them 
participated. Our study population is also older than many previous studies on CAH patients. 
In our first study (paper II) ten women and seven men were 50 years or older. 
 
We found remarkably fewer males than females. An autosomal recessive inheritance dictates 
equal sex distribution. Suprisingly, the differences in sex distribution was greater for SV than 
SW. We can only speculate if this is due to undiagnosed SV in adult men or increased 
neonatal mortality due to undiagnosed adrenal crises in the neonatal period, or other reasons. 
Paper I and the history above illustrate that SV in men can go undiagnosed or be diagnosed 
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late in life by chance. Fewer males with CAH are also reported from England (170) and in 
Sweden before the neonatal screening started (19;23).                                                                                         
 
Treatment 
Nearly all the patients received glucocorticoid therapy, and prednisolone was the mostly used 
glucocorticoid. Cortisone acetate came second.  Fewer of the Norwegian than the Swedish 
and English patients use fludrocortisone, 46% in Norway vs. 82% and 72% in Sweden and 
UK, respectively. This disparity is due to differences in the treatment of SV with 
mineralocorticoids. The fludrocortisone dose was similar in Norway and Sweden, but higher 
in the UK (58;59;134). Another difference is that we are using higher doses of 
glucocorticoids and more dexamethasone than the other two countries. Four of our patients 
had also undergone either unilateral, partial or total (one patient) adrenalectomy. This is not 
established treatment and is only likely to be used in patients with severe 21-OHD (null 
mutations) refractory to standard medical treatment. More studies are needed to find the 
optimal treatment for adult patients with CAH and to determine whether novel treatment such 
as modified-released HC tablets (51) or CSHI (52) will improve health outcome. We also 
need better guidelines for treatment and follow-up.  
 
HRQoL                                                                                                                       
HRQoL is a broad term, which is difficult both to define and evaluate. Many of the 
definitions of HRQoL is based on WHO’s expanded definition of health from 1946: “A state 
of complete physical, mental and social well-being and not merely the absence of disease or 
infirmity”.  Our findings of reduced HRQoL were supported by others, published a few 
months after our Paper II in 2010 (59). This implies that the majority of studies in CAH now 
show impaired HRQoL. The cause of impaired HRQoL is complex, including hormonal 
disturbances, genotype, steroid treatment, and psychological issues. Hopefully, systematic 
studies and increased knowledge about the disease can help the clinicians influence these 
result in a favourable direction. We compared the SF-36 results with other patient groups in 
Norway, showing that the CAH patients have similar HRQoL perception as patients with 
Addison’s disease, who also had pronounced impairment of general health and vitality (171). 
The scores were lower than in patients with renal transplant and Turner’s syndrome 
(172;173). Patients with rheumatoid arthritis had definitively the lowest score in all subscales 
when comparing SF-36 results (174) (Figure 4).  
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Figure 4. Studies of SR-36 subscales in different patient populations in Norway compared 
with normative data (154;171-176). Mean is given. 
 
 
 
Measuring HRQoL is difficult and the validity of SF-36 or other questionnaires for 
evaluation of this disease has limitations. It is well accepted that SF-36, which is a generic 
instrument, contains dimensions that are important for HRQoL. Generic forms make 
comparison with other diseases groups possible, and might be the best option, as no specific 
HRQoL questionnaire for CAH exists. A new disease-specific questionnaire has been 
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produced for Addison’s patients, AddiQoL (177;178), which could possibly be appropriate 
for HRQoL assessment in CAH patients. 
  
Another question is whether the patients estimate their HRQoL appropriately. In empirical 
studies the patients tend to assess their own health as better than considered by their healthy 
peers (179). Recall bias is often present in retrospective studies, where one group, usually the 
cases, recall events better than the references. Response bias occurs when respondents answer 
questions in the way they think the questioner wants them to answer rather than according to 
their true perception. Scale bias implies that subjects have different perceptions of what the 
scale of a phenomenon essentially measures. 
 
Working disability                                                                                                          
To our knowledge we are the only group to publish data on working ability in adult CAH 
patients. The disabled patients had significantly impaired SF-36 scales compared to the 
working patients, and we can only speculate if they have low scores due to the disability or 
vice versa. We did not find any special factors that correlated with the proportion of 
disability, be it glucocorticoid doses, hormone levels, sex differences, mutation groups, age at 
diagnosis or other parameters. However it may be assumed that patients with a chronic 
disease more easily obtain working disability benefits. A Norwegian study in patients with 
Addison’s disease showed similar results on working disability (171). 
 
Fertility in women                                                                                                                                               
Our results support the results from other studies showing low pregnancy rates among CAH 
women, especially in the SW (89-92). Several factors contribute. We found that many 
patients had irregular menstruations and long periods of amenorrhoea, but had never 
consulted a gynaecologist as adults. Regular gynaecological investigations are recommended 
in international literature (72). Forty-five percent of the Norwegian female patients had 
irregular menses compared to 28% of the Swedish. One main difference between these 
countries is the use of mineralocorticoids. A beneficial effect of adding fludrocortisone is the 
lowering of 17-OHP, which could favour ovulation (99). On the other hand, investigators 
have found normal fertility rates in those attempting conception, even in the SW group 
(97;99). Whether this observation can be generalised to all female patients remains to be 
shown, as these results were based on studies of few patients.   
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Concerning sex hormones in our female patients, the levels of FSH and LH were in the 
reference range in our patients below 50 years of age, and not increased as can be seen with 
polycystic ovary syndrome. On the other hand, high adrenal androgen levels and the 
glucocorticoid treatment might suppress the gonadotropins. Interestingly, all the seven 
women above 50 years had normal post-menopausal FSH and LH levels.                                                          
 
We think that the low birth rate and high single status in female with CAH, specially the SW, 
affects both the general quality of life and HRQoL, and must be considered a major problem 
for these patients. These issues should be given special attention by the clinicians treating 
them.  
 
Male fertility and TART 
We found TART only in the men with the SW form (57%), that is, the men with severe 
CYP21A2 mutations. The findings by Mouritsen et al. support these results. They looked 
specifically for the association between TART and CYP21A2 mutations, and found TART 
only in the men with the most severe mutations (groups Null and A); 73 % had TART in 
these groups and none in the more mildly affected groups B and C (180). Our results support 
Mouritsen’s theory that development of TART is determined by the mutations in the 
CYP21A2 gene.  
 
One accepted reason for development of TART is the elevation and stimulation of ACTH 
(112), and in line with this we found significantly higher levels of ACTH, 17-OHP and 
androstenedione in the men with TART than in men without. It has been shown that TART 
may regress when glucocorticoid therapy is given or intensified (116;181).  However, TART 
is also reported in men with good hormonal control (104).  
 
We found that the men in our study had testosterone levels in the lower normal range without 
tendency of increments in FSH and LH values as could be expected if a primary gonadal 
dysfunction due to TART was present. However LH and FSH levels are difficult to interpret 
in CAH because the gonadotropines may be suppressed by elevated adrenal androgens and 
glucocorticoids (182). Another issue is that we are measuring the hormone values in plasma 
or serum and we know little about the intracellular concentrations of steroids. 
Androstenedione may be converted in peripheral tissues to testosterone and oestrogens. One 
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study in healthy young men showed that after a 300 mg oral dose of androstenedione the 
serum levels of both oestrogens and testosterone increased. After 100 mg androstenedione 
only oestrogens increased. The serum levels of oestrogens and testosterone varied widely 
between the individuals (183).  
 
Only a few studies in men with CAH have examined paternity, with diverging results from 
normal to impaired (102;103). We found no overall reduction in fertility in the men and there 
was no difference in the number of children between the SW and the SV groups, even if 57% 
in the SW group had TART. However, we had no age-matched control group with which to 
compare fertility. This finding is in contrast to findings by Falhammar et al. in 30 CAH males 
that showed impaired fertility compared with age-matched national data (0.9± 1.3 vs.1.8± 0.5 
children/father ratio). Several studies in men with CAH show pathological semen analyses 
(104;105) indicating reduced fertility. We have not investigated semen quality in our patients. 
 
Adrenal tumours and adrenal size 
CT has until now been the gold standard for visualising the adrenal and to discover adrenal 
tumours. CT is also a more available modality than MR, so we decided to use CT even if we 
exposed the patients to radioactivity. Only two other studies have been performed to visualise 
the adrenals in CAH. The first study from Jaresch et al. in 1992 looked for adrenal tumours in 
22 CAH patients (107). The recent study from Reisch et al. evaluated adrenal size and 
adrenal tumours in 26 adult male with CAH (56). Both showed high frequencies of adrenal 
tumours at 82% and 73%, respectively, whereas we found only 11% in our study. However, 
the other studies did not characterise the tumours any further. One explanation for the large 
difference could be the way adrenal incidentalomas were defined; if nodules in macronodular 
hyperplasia are counted as solitary tumours the prevalence of adrenal incidentalomas will be 
high. Jaresch et al. intervened surgically in three patients with tumour size > six cm. 
Histological examination revealed one nodular hyperplasia, one adrenal adenoma, and one 
myelolipoma.  
 
It has been speculated if chronic elevation of ACTH may induce adrenal tumour growth in 
CAH. We found a positive correlation between morning ACTH and 17-OHP levels and 
adrenal dimensions, and significantly higher levels of ACTH in the patients with adrenals 
tumours than in those without. These results support the ACTH stimulation hypothesis. 
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Reisch et al. found a positive correlation between adrenal volume, tumour size and levels of 
andostenedione and 17-OHP, but not ACTH. However, they measured the hormones after 
intake of the glucocorticoid morning dose which would significantly lower several of these 
parameters.   
 
Reisch et al. did not report any myelolipomas and Jaresch et al. diagnosed one myelolipoma 
histologically after surgical intervention, whereas we detected six large myelolipomas 
radiologically in four (6.5%) of our patients. This is high compared with the normal 
population, where myelolipomas are reported in 1.5-8% of adrenal incidentalomas (184;185). 
To our knowledge, this is the first demonstration of high myelolipoma frequency in a large 
group of unselected patients with CAH. Myelolipomas have previously been associated with 
CAH in single cases, mostly after surgical intervention (57;186). Reisch et al. used MRI of 
the adrenals in their study, but the applied technique did not include fat suppression imaging 
that could have discriminated myelolipomas from adenomas. We believe the frequency of 
myelolipoma in patients with 21-OHD has been underestimated in previous studies. It is 
important that endocrinologist and radiologist are aware that these tumours may occur in 
CAH as myelolipomas are benign and asymptomatic tumours that usually need not be 
removed. Surgical excision is only to be considered in large myelolipomas above ten cm 
because of a possible risk of bleeding (109). Moreover, it is important to rule out CAH if an 
adrenal myelolipoma or adenoma is discovered. As early as 1950 Selye and Stone elegantly 
transformed adrenal tissue in rats into adipose and bone marrow elements by injecting them 
with an extract derived from the anterior pituitary gland along with methyltestosterone, and 
postulated that ACTH elevation could induce transformation of adrenal tissue into myeloid 
tissue (187). Sometimes the clue to the diagnosis in adults is a random CT finding of bilateral 
adrenal hyperplasia or myelolipoma (57;188).  
 
Reisch et al. and we both found normal adrenals in less than one third of the patients. Two 
thirds of our patients had hyperplasia. Interestingly, we also demonstrated adrenal hypoplasia 
in 11% of the patients, which may indicate overtreatment with glucocorticoids.  
                                                                                                                                                                               
Genetics  
Whether genotyping in CAH should be mandatory is debatable. The majority of our patients 
had not been genotyped before the inclusion in our study. In two cases, both of whom had 
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received glucocorticoid treatment for years, we did not find  mutations in CYP21A2 and 
scrutiny of their files lead to the conclusion that they were misdiagnosed. They were 
excluded from paper III and IV. One clear reason for genotyping is to verify the diagnoses 
especially in NCCAH. The Endocrine Society Clinical Practice Guidelines also recommend 
genotyping in adults with CAH and/or their partners before planning children, and genetic 
counselling is recommended for parents of a child with CAH and to adolescents at transition 
to adult care (2). Falhammar and Thorén recommend genotyping as their experience is that 
the clinical course can be predicted more precisely and serious consequences be prevented 
(46). They exemplify this with females with the Null genotype who are more severely 
affected with reduced fertility, impaired social functioning and psychosexual issues than 
other genotype groups. These patients need extra support and follow-up. Another issue is the 
importance of genotyping in research to discover new mechanism in CAH as i.e. P450 
oxidoreductase deficiency, which is due to mutations affecting P450 oxidoreductase  that 
serves as mandatory electron donor enzyme to all microsomal cytochrome p450 enzymes. 
The clinical manifestations of P450 oxidoreductase deficiency are adrenal insufficiency and 
neonatal DSD. 
 
The results of our mutation analyses show similar frequencies of the common CYP21A2 gene 
defects as those published from other Western European countries (30;31). We also confirm 
the earlier reported high genotype-phenotype correlations. Interesting a 54 year old male with 
CAH was diagnosed as SV and started treatment with glucocorticoids at 25 years of age. His 
older sister was diagnosed with SW at three months of age and two siblings had died as 
neonates. The genetic analyses showed deletion/large pseudogen conversion (5') consistent 
with genotype group null. He had large adrenals, small testicles and a height of 1.5 meters. 
We started treatment with mineralocorticoids due to large salt craving. This case is an 
unusual example of increasing aldosterone and cortisol deficiency with age and we have no 
reasonable explanation for this; or simply an example of late diagnosis and incorrect 
treatment in youth. 
 
We identified four novel CYP21A2 point mutations that are most likely pathogenic, as 
indicated by the following phenotypes: del/L388R and del/E140K were SW, whereas 
del/V211M, V281L and del/P45L were SV (novel mutations in italic). Ongoing functional 
studies of the mutated enzymes revealed no or reduced enzyme activities (Brønstad, 
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unpublished data).  
   
Clinical characteristics, BMD and blood pressure 
One striking result of our survey is the increased fat mass in CAH patients, especially in the 
young women. Increased fat mass is a major health problem in the population at large, and is 
a known risk factor for cardiovascular disease, diabetes and cancer. Obesity also increases the 
risk of infertility and could be a contributing factor to infertility in CAH women. In the 
transition from childhood to adulthood many CAH patients are switched to long acting 
synthetic glucocorticoids, which are much more potent and prone to give side-effects than the 
short-acting natural glucocorticoids. We believe it is important to avoid high doses and 
perhaps a short-acting glucocorticoid should also be recommended in adults. 
Mineralocorticoids should be used in addition when possible, as this could reduce the 
glucocorticoid doses. Measurement of body composition is not usually performed in general 
practice and BMI only rarely in adult CAH patients (personal experience), but these 
parameters might be important to optimise the treatment.    
 
The studies in BMD in adult patients with CAH are conflicting, and few studies have 
included men more than 30 years old (59;143). We found reduced BMD both in men and 
women and a high frequency of osteopenia, especially in the male patients. This could be due 
both to high glucocorticoid doses and lack of testosterone and vitamin D. We recommend 
regular monitoring of BMD in both men and women with CAH, which unfortunately was not 
discussed in the latest clinical guidelines (2).  
 
Surprisingly, the patients have higher diastolic blood pressure than the normal population, 
despite that the glucocorticoid or mineralocorticoid doses in the morning were not taken 
before the measurement. Arlt et al. reported the same finding, however only for females (59). 
Elevated diastolic blood pressure has also been reported in Addison patients and the 
mechanism for this was speculated to be high doses of mineralocorticoid (189). 
 
Biochemical findings  
Few of the female patients had testosterone levels in the normal range and many had 
suppressed androgens, indicating overtreatment with glucocortioids. Arlt et al. and 
Falhammar et al. reported similar findings (58;59), demonstrating that optimal glucocorticoid 
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treatment in CAH is difficult. Half of our patients had 17-OHP levels above the upper 
recommended target range; again the same phenomenon has been seen in other populations 
(59). The value of a single measurement of 17-OH is debatable, but gives some information. 
We found larger adrenals and higher frequency of TART in patients with high morning levels 
of 17-OHP, suggesting that single measurement of 17-OHP can be informative. We did not 
show any differences from reference values in lipids, lever enzymes or glucose metabolism in 
our patients. The CAH patients, especially the women, had low vitamin D levels and one 
contributing factor to this could be the increased fat mass. Lower concentrations of serum 25-
hydroxyvitamin D levels in obese subjects may be explained by enhanced uptake by adipose 
tissue and increased metabolic clearance. A sedentary lifestyle with less exposure to sunlight 
could also contribute (190). We recommend regularly monitoring of vitamin D and 
replacement of low levels.  
 
 
METHODOLOGICAL ASPECTS/LIMITATIONS 
 
The principal limitation to the interpretation of our data is that we did not have age and sex 
matched control populations. Some analyses utilised matched control data drawn from the 
previous HUNT 3 study. The HRQoL data were compared with a Norwegian reference 
population published ten years ago, and other data were compared with the reference data 
given by the manufactures of DXA machines or laboratories. Concerning fertility, semen-
analyses in the men and analysis of inhibin B and oestradiol in both women and the men 
would have added value to the study. Small cohorts limit the certainty of the analysis of 
frequencies of adrenal tumours, TART, and might contribute to low statistical power to detect 
significant associations, for instance between hormonal control and tumour size or between 
mutation groups or other parameters. Larger multicentre studies are needed to obtain further 
knowledge about this patient group.       
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CONCLUSIONS           
 
The studies of adult Norwegian patients with CAH have shown that 
 
x The recorded incidence of CAH due to 21-OHD of one in 20 000 in Norway is lower 
than the expected incidence of one in 15 000, with a lower incidence in men than in 
women. Untimely, deaths and insufficient treatment may be avoided by screening of 
neonates. 
x Gene deletions/conversions, I2 splice and the point mutation I172N were as frequent 
as expected, and four novel disease-causing CYP21A2 mutations were identified. 
x Patients with CAH, as a group, have reduced physical and mental health perception 
and especially reduced scores for general health and vitality perception; working 
disability is increased. 
x Women with CAH have impaired fertility, most pronounced in the SW. 
x CAH patients have an increased frequency of adrenal tumours, particularly 
myelolipomas.  
x BMI, fat mass and diastolic blood pressure is increased in CAH patients. The findings 
may indicate increased risk for cardiovascular disease. 
x CAH patients have high frequencies of osteopenia and osteoporosis, but whether 
fracture rates are increased is not known. 
x Hormonal parameters were poorly controlled. There is a need for a more systematic 
approach to therapy and more studies on replacement therapy. 
      
Taken together, our findings most likely reflect inappropriate glucocorticoid and 
mineralocorticoid replacement. Improvement in the clinical management of adults with CAH 
is required, and we suggest that these patients be followed by endocrinologists, and that 
international guidelines are followed. More research is needed to fill the gap in knowledge in 
areas such as replacement therapy, fertility, and the understanding of psychoendocrinological 
factors involved in subjective health status and working ability.  
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We present incidentally discovered adrenal myelolipomas in two adult males with untreated congenital adrenal hyperplasia
(CAH). The patients had simple virilizing form of CAH due to mutations in the CYP21 gene coding for 21-hydroxylase; one was
heterozygous for the I172N mutation and the other compound heterozygous for the I172N and I2splice mutations. The masses
were not removed since myelolipomas are considered benign tumors, and the tumor size did not increase during four- and nine-
year observation periods. An adrenal myelolipoma is an important exception to the rule that large tumours should be removed.
Untreated CAH with prolonged excessive ACTH stimulation might contribute to the growth of adrenal masses. CAH should be
considered as a diﬀerential diagnosis of patients with adrenal masses or adrenal myelolipomas.
Copyright © 2009 Ingrid Nermoen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Adrenal incidentalomas are common; the challenge is to rule
out malignancy or excess hormone secretion [1]. Myelolipo-
mas are benign endocrine inactive tumors composed of
adrenal, adipose, and myeloid tissue, representing 1.5%–9%
of adrenal incidentalomas; the radiological characteristic is
round, sharp-demarcated lesion with negative attenuation
values because of its high fat content [2–5]. Large adrenal
masses should usually be removed, but myelolipomas usually
do not need resection. However, many of the reported cases
were diagnosed after adrenalectomy. Rarely, myelolipomas
have been associated with hormone excess syndromes,
such as congenital adrenal hyperplasia (CAH) [6–10]. We
here report two cases, which illustrate that large adrenal
myelolipomas need not to be surgically removed and that
CAH must be considered in patients with adrenal inciden-
talomas.
2. Case Report 1
In 1999 a 50-year-old man presented with a right adrenal
mass 5.7 × 5.1 × 1.9 cm. Medical history revealed precocius
puberty at age 4, and he was diagnosed with “Morbus Glan-
dulae Suprarenalis” when he was 9. Urinary 17-ketosteroids
were found elevated, but suppressible with dexamethasone.
He was treated with cortisone acetate 12.5 mg thrice daily
from age 9, but at 18 he stopped the medication, after which
he felt that his general wellbeing is improving. After this time
he was lost to follow-up. At the age of 37 he underwent
radioiodine treatment for thyrotoxicosis. He was otherwise
healthy, working full time, and was the father of one child.
In spite of radioiodine treatment he felt he had persistent
goitre, and his general practitioner referred him to a cervical
CT, which due to his short stature included the upper
abdomen. Pronounced bilateral adrenal hyperplasia and a
5.7 cm in diameter tumor described as a typical adrenal
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Figure 1: Computed tomography of the adrenals in Patient 1.
(a) Arrows show a 5.7 centimetre large, expansive process in the
right adrenal with a heterogeneous stroma, fat, calciﬁcations, and
in addition, pronounced bilateral adrenal hyperplasia. Magnetic
resonance images of the adrenal tumor , T1 Weighted Imaging, with
hyperintense fat (b) showing signal loss in fat suppressed image (c).
myelolipoma (capsule, heterogeneous stroma, and fat in the
adrenal mass) was found (Figure 1).
Further investigation revealed height 164 cm, weight
76 kg, and blood pressure 120/80 mmHg. On palpation the
Table 1: Myelolipoma: baseline measurements and endocrinologi-
cal test results.
Patient 1 Patient 2 Normal
Baseline
ACTH, pmol/L 6–32.8∗ 10.9–94.2 (2–13)
Cortisol, nmol/L 210 387 (250–750)
17 OH-progesterone,
nmol/L
>605 445 (<6)
DHEAS, μmol/L 14.4 1.8 (6–12)
Androstendione, nmol/L 43.8 10.9 (<5.6)
Testosterone, nmol/L 11.7 10.1 (10–40)
ACTH stimulation∗∗
Cortisol 30 minutes,
nmol/L
211 409
Cortisol 60 minutes,
nmol/L
231 412 (>550)
17 OH-progesterone 30
minutes, nmol/L
>605 445
17 OH-progesterone 60
minutes, nmol/L
>605 560 (<30)
Dexamethasone
suppression∗∗∗
Cortisol, nmol/L 22 45 (<50)
17 OH-progesterone,
nmol/L
14.3 18.8
∗
Most values in the higher range. ∗∗Corticotropin (250 ug i.v.). ∗∗∗1 mg
overnight test in Patient 2 and 0.5 mg × 4 for 2 days in Patient 1.
patient had no enlargement of the thyroid gland. Genital
examination showed normal penile size and subnormal tes-
ticular volume of 12 mL bilaterally. Biochemical investigation
revealed low basal cortisol, which did not increase after
ACTH stimulation (Table 1). He had a high basal level of
17-OH-progesterone, typical of 21-hydroxylase deﬁciency,
which was suppressed after a conventional dexamethasone
test (Table 1). DNA sequencing of the CYP21 (steroid 21-
hydroxylase) gene revealed the c. 515T > A point mutation,
which results in the predicted amino acid change I172N.
The mutation was present in hemi- or homozygous form
(i.e., the genotype was I 172N/deletion or I172N/I172N).
The adrenal mass caused no symptoms and was considered
highly likely benign and therefore left untreated. The tumor
and hyperplasia did not change radiologically over a nine-
year subsequent observation period. The patient continues
to do well without steroid medication, but is instructed to
take steroids during stress.
3. Case Report 2
A previously healthy 68-year-old man, father of one child,
presented in 1994 with fatigue and nausea. For many
years he had suﬀered arthralgic pain and had been treated
with antiﬂogistics. The last months he had experienced
problems with nocturia and impotence. He was referred
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to ultrasonography of the abdomen, on which a tumor
in the right adrenal was detected. An adrenal CT scan
showed a 4× 4× 2.5 cm tumor in the right adrenal with
high fat content, which was radiologically considered to be
a myelolipoma. The left adrenal was evaluated as normal.
Further clinical investigation showed height 165 cm,
blood pressure 140/80 mmHg, and normal male genitalia
with testicular tenderness bilaterally. Biochemical investiga-
tion showed high basal level of 17-OH-progesterone, which
was suppressible with dexamethasone, and an impaired
cortisol response to ACTH stimulation (Table 1). Adrenal
iodomethyl-19-norcholesterol scintigraphy showed high
uptake in the right adrenal, which however was suppressed
by dexamethasone; uptake was normal or low in the left
adrenal. DNA sequencing of CYP21 revealed compound
heterozygozity for the I172N mutation (c. 515T > A) and the
I2 splice mutation (g.655A/C > G, I172N/I2splice).
The myelolipoma was not removed and the tumor size
did not increase during a four-year observation period. The
patient was started on treatment with 5 mg prednisolone
daily for one year, later cortisone acetate 12.5 mg twice a
day whereupon his condition improved. The patient died
suddenly, 73 years old, in his home; the cause of death
remains unknown.
4. Discussion
We here report two male patients who presented late in life
with large adrenal myelolipomas. One was previously treated
for CAH, whereas one was diagnosed with 21-hydroxylase
deﬁciency after being diagnosed with the adrenal tumor at
68 years of age. Both tumors were left untreated and did not
grow over ﬁve- and nine-year observation periods.
An adrenal mass normally requires surgical removal if
the largest diameter exceeds 3 cm [1]. Undiagnosed CAH
must always be considered as a diﬀerential diagnosis to
tumor, particularly with bilateral adrenal masses. Adrenal
myelolipomas are benign and usually asymptomatic tumors
that usually need not to be resected [2, 6, 7, 11]. Many
of the cases that have been reported in literature were
diagnosed after adrenalectomy [2, 6, 7, 11]. The imaging
characteristics of myelolipomas usually allow presumptive
diagnosis, but which may be conﬁrmed by percutaneous
needle biopsy in cases of extra-adrenal myelolipomas
[5].
However, large myelolipomas could be dangerous if
they start bleeding and give symptoms with pain, nausea,
vomiting, and hypotension [2]. Because of mass eﬀects and
the risk of haemorrhage, elective removal of myelolipomas
that exceed 10 cm in diameter might be considered.
Increased prevalence of adrenal tumors has been
reported in CAH patients and in heterozygote mutation
carriers, possibly due to increased levels of ACTH which
acts as a growth factor [12–15]. It has been suggested
that inadequate glucocorticoid coverage in early life or
frequent episodes of infection, both resulting in chronic
ACTH increase, contribute to the development of adrenal
tumors later in life [15, 16]. The aetiology is unknown, but
several theories have been proposed, such as development
from residual embryonic mesenchymal tissue in the adrenal
glands, or metaplasia of reticuloendothelial cells as a result of
chronic stress [2].
It was postulated early in the 1950s that ACTH ele-
vation might induce transformation of adrenal tissue into
myeloid tissue [17], and myelolipomas could thus be par-
ticularly associated with CAH. Hagiwara et al. investigated
ACTH receptors and androgen receptor in a resected giant
myelolipooma in a woman with CAH. They did not
ﬁnd that the receptors were overexpressed and suggest a
limited direct role for these hormones in the develop-
ment of the myelolipoma [18]. However this conclusion is
debatable.
To our knowledge less than 20 cases of adrenal myelolipo-
mas have been reported in patients with CAH to date [7–
10, 16, 18–20]. Jaresch et al. found adrenal masses in 83% of
CAH patients and 45% of heterozygous CYP21 mutation car-
riers, which is high compared to the general population [13].
However, their study included only 22 homozygous CAH
patients and 20 heterozygous siblings. Conversely, series of
adrenal incidentalomas have been tested for germline CYP21
mutations, showing inconsistent results which could be due
to small samples [12, 13, 15]. Consequently, it appears that
adrenal masses are common in CAH, but that CAH is not a
common cause of adrenal masses.
The diagnosis of CAH in a patient with an incidental
adrenal mass is important as the patient is at risk of adrenal
crises [21]. Such patients may beneﬁt from glucocorticoid
therapy and should at least be equipped with emergency
medication and a medical alert card. Patient 1 had a
blunted cortisol response to ACTH stimulation, but he had
managed well for 30 years without steroids, working full-
time and did not want to take steroids because of the
psychological side eﬀects he experienced during adolescence.
He was nonetheless advised to take steroids under stressful
situations. Patient 2 had higher basal level of cortisol,
but suboptimal cortisol response to ACTH stimulation. He
had symptoms of cortisol deﬁciency, and his condition
improved considerably after treatment with prednisolone
was commenced. He had a low normal testosterone level
and tenderness of the testicles. This could be the result
of testicular adrenal rest tumors but was not investigated
further. Whether glucocorticoid suppression therapy in
adult age halts further growth of the tumor is uncertain.
In our patients the tumors did not grow over four to
nine year observation periods despite high ACTH levels.
Conversely, Rajput et al. described progressive evolution of
an adrenal myelolipoma in a woman with CAH who was
treated with prednisolone, although taken irregularly, ren-
dering the level of 17-OH-progesterone persistently elevated
[19].
In conclusion, congenital adrenal hyperplasia, per se,
should be included in the diﬀerential diagnosis of adrenal
masses. If suspected clinically, assay of cortisol, ACTH, and
17OH-progesterone should be performed. Adrenal tumors
are common in CAH and might require surgical removal,
but myelolipomas are benign tumors that usually can be left
untreated. Whether, treatment of CAH halts myelolipoma
growth is uncertain.
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